Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0002001011-25-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-06 | 2025-03-04 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +7,484 | 26.4K | +40% | $0 |
| D | 2025-03-06 | 2025-03-04 | LGND | Espinoza Octavio | CFO | S - Sale | $115.03 | -5,000 | 18.9K | -21% | -$575.1K |
| D | 2025-03-06 | 2025-03-04 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +32.7K | 32.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | A | A | 7,484 | $0.00 | 26,363 | D | — | — | (F2) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Common | Common Stock | 2025-03-04 | S | D | 5,000 | $115.03 | 18,879 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.8900 to $115.1850, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-03-04 | A | A | 32,717 | $0.00 | 32,717 | D | $115.26 · — to 2035-03-04 | 32,717 Common Stock | (F3) The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. |